Sean Laaman
Stock Analyst at Morgan Stanley
(4.50)
# 291
Out of 5,149 analysts
26
Total ratings
75%
Success rate
15.51%
Average return
Main Sectors:
Stocks Rated by Sean Laaman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EIKN Eikon Therapeutics | Initiates: Overweight | $32 | $14.88 | +115.05% | 1 | Mar 2, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $96 → $98 | $65.50 | +49.62% | 2 | Feb 25, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $48 → $49 | $41.03 | +19.42% | 6 | Feb 2, 2026 | |
| AXSM Axsome Therapeutics | Downgrades: Equal-Weight | $196 → $204 | $166.38 | +22.61% | 4 | Jan 8, 2026 | |
| CERT Certara | Maintains: Equal-Weight | $16 → $12 | $7.05 | +70.21% | 2 | Dec 18, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Overweight | $20 | $10.08 | +98.41% | 1 | Dec 5, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Overweight | $34 | $17.60 | +93.18% | 1 | Nov 21, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $90 → $115 | $66.54 | +72.83% | 3 | Oct 30, 2025 | |
| RMD ResMed | Maintains: Overweight | $298 → $304 | $257.39 | +18.11% | 2 | Oct 21, 2025 | |
| ONC BeOne Medicines AG | Maintains: Overweight | $350 → $383 | $314.36 | +21.83% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $3 → $1.5 | $2.21 | -32.13% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $67 | $69.85 | -4.08% | 1 | Feb 14, 2025 |
Eikon Therapeutics
Mar 2, 2026
Initiates: Overweight
Price Target: $32
Current: $14.88
Upside: +115.05%
BridgeBio Pharma
Feb 25, 2026
Maintains: Overweight
Price Target: $96 → $98
Current: $65.50
Upside: +49.62%
Exelixis
Feb 2, 2026
Maintains: Equal-Weight
Price Target: $48 → $49
Current: $41.03
Upside: +19.42%
Axsome Therapeutics
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $196 → $204
Current: $166.38
Upside: +22.61%
Certara
Dec 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $12
Current: $7.05
Upside: +70.21%
BridgeBio Oncology Therapeutics
Dec 5, 2025
Initiates: Overweight
Price Target: $20
Current: $10.08
Upside: +98.41%
MapLight Therapeutics
Nov 21, 2025
Initiates: Overweight
Price Target: $34
Current: $17.60
Upside: +93.18%
Disc Medicine
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $115
Current: $66.54
Upside: +72.83%
ResMed
Oct 21, 2025
Maintains: Overweight
Price Target: $298 → $304
Current: $257.39
Upside: +18.11%
BeOne Medicines AG
Oct 20, 2025
Maintains: Overweight
Price Target: $350 → $383
Current: $314.36
Upside: +21.83%
Mar 7, 2025
Assumes: Underweight
Price Target: $3 → $1.5
Current: $2.21
Upside: -32.13%
Feb 14, 2025
Assumes: Overweight
Price Target: $67
Current: $69.85
Upside: -4.08%